SMOC2介导GLI1+间充质细胞驱动克罗恩病纤维狭窄并预测术后复发
该研究探讨GLI1+间充质细胞在克罗恩病纤维狭窄中的作用及其治疗潜力。通过单细胞转录组测序、谱系追踪和小鼠模型,发现GLI1+间充质细胞在纤维化部位富集并分化为肌成纤维细胞,通过分泌SMOC2促进细胞外基质沉积和成纤维细胞活化。在手术CD队列中,肠道组织高SMOC2表达与术后复发相关,提示SMOC2可作为预测术后复发的生物标志物和潜在治疗靶点。
要点
- GLI1+间充质细胞在CD纤维化部位富集并驱动纤维狭窄。
- SMOC2介导GLI1+间充质细胞促纤维化作用。
- 高SMOC2表达与CD术后复发相关。
核心结论
- GLI1+间充质细胞通过SMOC2介导的微环境形成驱动肠道纤维狭窄。
- SMOC2可作为预测CD术后复发的生物标志物和潜在治疗靶点。
研究设计与样本
- 收集接受纤维狭窄梗阻手术的CD患者纤维化和非纤维化组织样本。
- 使用DSS或TNBS诱导小鼠慢性结肠炎。
- 对人及小鼠肠道组织进行单细胞RNA测序。
- 使用Gli1-CreERT2; R26-tdTomato和Gli1-CreERT2; R26-iDTR小鼠进行谱系追踪和靶向细胞消融。
- 分析手术CD纤维狭窄队列并在验证队列中确认。
主要发现
- 单细胞转录组学和免疫荧光显示GLI1+间充质细胞在纤维化部位富集。
- 谱系追踪显示这些细胞在慢性结肠炎中扩增并获得肌成纤维细胞表型,而消融这些细胞可减轻纤维化。
- GLI1+间充质细胞高表达SMOC2,SMOC2在人和小鼠纤维化中上调,体内外敲低SMOC2可减轻纤维化。
- GLI1+间充质细胞分泌SMOC2,促进细胞外基质沉积和成纤维细胞活化。
- 在手术CD队列中,肠道组织高SMOC2表达与术后复发相关,并在验证队列中确认。
临床怎么用
- SMOC2高表达可能用于预测CD术后复发风险。
- 靶向GLI1+间充质细胞或SMOC2可能成为CD纤维狭窄的潜在治疗策略。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Fibrostenosis is a common and disabling complication of Crohn's disease (CD) with no reliable early biomarkers, limited treatment options and high postoperative recurrence. OBJECTIVE: To investigate the contribution of glioma-associated oncogene homolog 1 (GLI1+) mesenchymal cells to fibrostenotic progression and their potential as a therapeutic target. DESIGN: Fibrotic and non-fibrotic tissue samples were collected from patients with CD undergoing surgery for fibrostenotic obstruction. Chronic colitis was induced in mice using dextran sodium sulfate (DSS) or 2,4,6-trinitrobenzene sulfonic acid (TNBS). Single-cell RNA sequencing was performed on human and murine intestinal tissues. Gli1-CreERT2; R26-tdTomato and Gli1-CreERT2; R26-iDTR mice were used for lineage tracing and targeted cell ablation. GLI1+ mesenchymal cells were isolated to identify pathogenic determinants. A surgical CD fibrostenosis cohort was analysed. RESULTS: Single-cell transcriptomics and immunofluorescence revealed enrichment of GLI1+ mesenchymal cells at fibrotic sites. Lineage tracing showed that these cells expanded and adopted a myofibroblast phenotype in chronic colitis, whereas their ablation alleviated fibrosis. GLI1+ mesenchymal cells exhibited a distinct transcriptional expression profile with prominent expression of SPARC-related modular calcium-binding protein 2 (SMOC2). SMOC2 was upregulated in human and murine fibrosis, and its knockdown in vivo and in vitro attenuated fibrosis. Mechanistically, GLI1+ mesenchymal cells secreted SMOC2, promoting extracellular matrix deposition and fibroblast activation. In surgical CD cohorts, high SMOC2 expression in intestinal tissue correlated with postoperative recurrence, confirmed in the validation cohort. CONCLUSION: GLI1+ mesenchymal cells drive intestinal fibrostenosis through SMOC2-mediated niche formation. SMOC2 may serve as a predictive biomarker for postoperative recurrence and a potential therapeutic target for CD.
引用
- Wang D, Zhao X, Yang Q, et al. SMOC2 mediates GLI1+ mesenchymal cell-driven fibrostenosis and predicts postoperative recurrence in Crohn's disease. Gut. 2026. PMID: 42419822. doi:10.1136/gutjnl-2025-337952
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。